Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| January 12, 2018 | Ordinary Shares (25p) | £13.4755 | 26 | Acquisition (Dividend Re-investment) |
| January 12, 2018 | Ordinary Shares (25p) | £13.4755 | 22 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by two executives via dividend re-investment plans within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share purchases.
Key Facts for Investor Verification
- Transaction Nature: Both reported transactions were acquisitions of ordinary shares resulting from the re-investment of dividends paid on January 12, 2018.
- Executives Involved:
- Mr. D S Redfern (Chief Strategy Officer): Acquired 26 shares.
- Mrs. V A Whyte (Company Secretary): Acquired 22 shares.
- Market Data: Transactions occurred on the London Stock Exchange (XLON) at a price of £13.4755 per share.
- Account Type: Shares were held within an ISA (Individual Savings Account).